<SEC-DOCUMENT>0001493152-20-006853.txt : 20200421
<SEC-HEADER>0001493152-20-006853.hdr.sgml : 20200421
<ACCEPTANCE-DATETIME>20200421165432
ACCESSION NUMBER:		0001493152-20-006853
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200415
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200421
DATE AS OF CHANGE:		20200421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		20805784

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported): April 15, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-15771</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>83-0221517</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
        incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1330
Avenue of the Americas, 33rd Floor,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>(646)
813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, $0.01 par value</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEO</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Appointment
of New Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2020, the Board of Directors (the &ldquo;Board&rdquo;) of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) appointed
Brian J.G. Pereira, M.D. and Shawn Tomasello to serve on the Board effective immediately. Dr. Pereira will serve as a Class 3
director whose term will expire at the Company&rsquo;s annual meeting of stockholders to be held in 2022, and Ms. Tomasello will
serve as a Class 2 director whose term will expire at the Company&rsquo;s annual meeting of stockholders to be held in 2021. Effective
upon the appointment of Dr. Pereira and Ms. Tomasello to the Board, Mark J. Alvino and Richard Van Duyne resigned from the Board,
consistent with their previously-disclosed resignation letters. In addition, the Board has appointed Dr. Pereira as Executive
Chairman.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Pereira is not expected to serve on any committees of the Board. Ms. Tomasello is expected to be appointed to the Nominating and
Governance Committee and Audit Committee of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Pereira and Ms. Tomasello were each nominated pursuant to a letter agreement dated as of December 20, 2019 (the &ldquo;Letter
Agreement&rdquo;), between the Company and affiliates of Great Point Partners, LLC (&ldquo;Great Point&rdquo;), an existing stockholder.
The Letter Agreement granted Great Point the right to nominate two members to the Company&rsquo;s Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s former Executive Chairman, Steven H. Rouhandeh, resigned from that position effective upon Dr. Pereira&rsquo;s
appointment, consistent with Mr. Rouhandeh&rsquo;s separation agreement entered into on January 2, 2020. As previously disclosed,
Mr. Rouhandeh will continue to serve as a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a non-employee director, Ms. Tomasello will receive the same compensation as the other non-employee directors of the Company under
the standard arrangements and agreements described in the Company&rsquo;s 2020 Annual Meeting Proxy Statement, including cash
compensation, prorated from Ms. Tomasello&rsquo;s appointment, and equity awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has determined that Ms. Tomasello qualifies as an &ldquo;independent director&rdquo; as defined under Nasdaq Listing Rule
5605(a)(2). The Company is not aware of any transaction or relationship involving Dr. Pereira or Ms. Tomasello requiring disclosure
under Item 404(a) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Brian
Pereira&rsquo;s Offer Letter</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the offer letter dated April 15, 2020 (the &ldquo;Offer Letter&rdquo;), by and between Dr. Pereira and the Company, for his
services as Executive Chairman, Dr. Pereira will receive an annual retainer of $375,000, payable in accordance with regular payroll
practices of the Company. Dr. Pereira will also be entitled to an annual bonus opportunity, with a target range equal to 50% of
his annual retainer and prorated for any partial year of service. Any such bonus will be contingent on Dr. Pereira&rsquo;s satisfaction
of objective and subjective performance goals established by the Board. Additionally, Dr. Pereira was granted options to purchase
930,000 shares of common stock of the Company. Such options were granted as an inducement grant under Nasdaq Listing Rule 5635(c)(4)
and outside of the Company&rsquo;s 2015 Equity Incentive Plan, but will generally have terms and conditions consistent with those
set forth in that plan. The options have an exercise price of $2.50 per share, which is equal to the closing price of Abeona&rsquo;s
common stock on the date of grant. The options have a 10-year term and will vest 25% on the one-year anniversary of the grant
date and in equal monthly installments over the following three years. Additionally, 100% of the options will be accelerated in
the event of certain qualifying terminations of Dr. Pereira&rsquo;s relationship following a change of control of the Company.
As Executive Chairman, Dr. Pereira also will be eligible for a grant of annual stock options. Such grants shall be in the sole
discretion of the Board, but is anticipated to be approximately equal to 75% of the stock options granted to the Company&rsquo;s
Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Pereira and the Company may each terminate the relationship for any reason upon written notice to the other party. If the relationship
is terminated for any reason, Dr. Pereira will be entitled to (i) payment of any retainer earned but unpaid through the Termination
Date (as such term is defined in the Offer Letter); (ii) payment of additional vested benefits, if any, in accordance with the
applicable terms of applicable Company arrangements; (iii) any unreimbursed expenses in accordance with the Company&rsquo;s business
expense reimbursement policies; and (iv) if Dr. Pereira&rsquo;s relationship is terminated by the Company without cause, Dr. Pereira
is entitled to receive as severance an amount equal to the retainer, payable over the one-year period following his termination.
The Company&rsquo;s obligations in the preceding sentence are conditioned upon, among other things, Dr. Pereira&rsquo;s execution
of a release of claims in favor of the Company and its affiliates. The foregoing summary of the Offer Letter does not purport
to be complete and is subject to, and qualified in its entirety by, the full text of the Offer Letter filed as Exhibit 10.1 herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Appointment
of Principal Financial Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on April 15, 2020, the Board appointed Edward Carr, the Company&rsquo;s Vice President and Chief Accounting Officer, as Principal
Financial Officer. The Company is not aware of any transaction or relationship involving Mr. Carr requiring disclosure under Item
404(a) of Regulation S-K. No material contract, plan, or arrangement was entered into in connection with this appointment. Mr.
Carr&rsquo;s compensation has not changed as a result of this appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01 Regulation FD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued a press release, dated April 21, 2020, announcing the appointment of Dr. Pereira and Ms. Tomasello to
the Board. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information furnished
in Exhibit 99.1 hereto shall not be considered &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor shall it be incorporated
by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless
the Company expressly sets forth in such future filings that such information is to be considered &ldquo;filed&rdquo; or incorporated
by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter, dated April 15, 2020, between Abeona Therapeutics Inc. and Brian J.G. Pereira, M.D.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated April 21, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
21, 2020</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward G. Carr</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    G. Carr</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Accounting Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
        15, 2020</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
        J. G. Pereira, MD</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-underline-color: black; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="height: 63.75pt; width: 186.75pt"></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Pereira,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
am pleased to offer you the position of Executive Chairman of Abeona Therapeutics Inc. (the &ldquo;<U>Company</U>&rdquo;) effective
April 15, 2020 (the &ldquo;<U>Effective Date</U>&rdquo;). You shall report directly to the Board of Directors of the Company (&ldquo;<U>Board</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Duties</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the position as Executive Chairman, you shall perform such duties, functions and responsibilities as are commensurate with such
position, as reasonably and lawfully directed by the Board and pursuant to which all officers and other employees of the Company
shall report directly or indirectly to you. You shall be appointed to the Board as a Class III director, effective immediately,
with a term expiring at the Company&rsquo;s 2022 Annual Meeting of Stockholders. You shall, if later requested by the Board, also
serve as a member of the Board of any corporation, organization, association, partnership, sole proprietorship, or other type
of entity, directly or indirectly controlling, controlled by, or under direct or indirect common control with the Company for
no additional compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Time Obligation</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Executive Chairman you shall devote an amount of your business time and attention sufficient to successfully carry out your duties
as Executive Chairman, shall faithfully serve the Company, use your best efforts to promote and serve the interests of the Company
and shall not engage in any other business activity, whether or not such activity shall be engaged in for pecuniary profit, that
conflicts with the foregoing obligation. However, nothing herein shall preclude you from continuing in your role as CEO of Visterra,
Inc. and performing all duties and obligations in connection therewith, engaging in charitable or community affairs and managing
your personal, financial, and legal affairs, so long as such activities do not materially interfere or conflict with your carrying
out your duties and responsibilities under this offer letter. Notwithstanding the foregoing, you will be permitted to act or serve
as a director or member of the boards of those companies on which you currently serve as previously disclosed to the Board and
such other private or public companies with the express written consent of the Board which consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
For your services described in this offer letter, you will receive an annual retainer of $375,000 USD, payable in accordance with
the regular payroll practices of the Company (&ldquo;<U>Retainer</U>&rdquo;). You will additionally be entitled to an annual bonus
opportunity, which is generally expected to track the bonus opportunity provided to the Company&rsquo;s CEO, with a target range
equal to 50% of your annual retainer and prorated for any partial year of service. Any such bonus will be contingent upon your
satisfaction of objective and/or subjective performance goals as established in the sole discretion of the Board (or a designated
committee of the Board). To be eligible to receive the bonus, you must remain affiliated with the Company on the date of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As of the Effective Date, you will be granted 930,000 options to purchase common stock of the Company under the Company&rsquo;s
Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) at an exercise price equal to the fair market value of the common stock
on the date of grant. Such options will vest over a four-year period in accordance with the Plan and the Company&rsquo;s standard
vesting schedule and are subject to the terms and conditions of the Plan and the Company&rsquo;s standard form of option agreement
under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
While you are Executive Chairman, on an annual basis (commencing in 2021) you will be eligible for annual stock option grants.
The amount of such grants shall be in the sole discretion of the Board, but it is anticipated that such grants will be approximately
equal to 75% of the stock options granted to the Chief Executive Officer. Any such grants will have an exercise price per share
equal to the fair market value of the common stock on the date of grant and will be subject to the terms and conditions of the
Plan (or a successor plan) and an applicable option agreement thereunder (including vesting terms and conditions to be established
by the Board or a designated committee thereof at the time of grant).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If, following any termination of your employment as CEO of Visterra, Inc., you become a full-time employee of the Company, you
shall be entitled to participate in the Company&rsquo;s employee benefit plans in accordance with their terms and eligibility
conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may terminate its relationship with you for any reason, and you may voluntarily terminate your relationship with the Company
hereunder for any reason, in each case at any time upon written notice to the other party (the date on which your relationship
terminates for any reason is herein referred to as the &ldquo;<U>Termination Date</U>&rdquo;). Upon the termination of our relationship,
you (or your beneficiary or estate, as applicable, in the event of your death) will be entitled to (i) payment of any retainer
earned but unpaid through the Termination Date, (ii) additional vested benefits (if any) in accordance with the applicable terms
of applicable Company arrangements, (iii) any unreimbursed expenses in accordance with the Company&rsquo;s business expense reimbursement
policies (collectively, the &ldquo;<U>Accrued Amounts</U>&rdquo;) and (iv) if your relationship is terminated by the Company without
cause (and other than by reason of your death or disability), you shall be paid as severance an amount equal to the retainer,
payable on the Company&rsquo;s normal payroll schedule over the 1-year period following such termination (the &ldquo;<U>Severance</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing payments and benefits upon termination of your relationship shall constitute the exclusive payments and benefits due
to you upon a termination of your relationship. The Severance will be subject to your execution of a general release of claims
in favor of the Company and its affiliates in a form acceptable to the Company within 60 days following your termination by the
Company without cause and your continued compliance with post-relationship obligations similar to those of the current Chief Executive
Officer as in effect as of the date hereof, including without limitation, non-competition and non-solicitation covenants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
your termination of your relationship with the Company for any reason, you will be deemed to have resigned, as of the Termination
Date, from all positions you then hold with the Company and its affiliates, including your position as a member of the Board.
Upon termination of your relationship, you agree to submit your resignation as a Director of the Company (and from any other positions
you hold with the Company and its affiliates) to the Board in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the termination of your relationship with the Company for any reason, you will reasonably cooperate with the Company upon reasonable
request of the CEO or the Board and be reasonably available to the Company (taking into account your other business endeavors)
with respect to matters arising out of your services to the Company and its subsidiaries, including, in connection with any legal
proceeding, providing testimony and affidavits; <U>provided</U>, <U>that</U>, the Company shall make reasonable efforts to minimize
disruption of your other activities. The Company shall reimburse you for reasonable expenses incurred in connection with such
cooperation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restrictive Covenants</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is subject to the Company&rsquo;s policies contained in the Employee Handbook, the Policy on Insider Trading, Whistle Blower
Policy, Code of Ethics, and the terms of any Employee Confidentiality Non-competition and Proprietary Information Agreement between
you and the Company, the terms of which are incorporated by reference. You will also be subject to non-competition and non-solicitation
provisions consistent with those of the Chief Executive Officer as in effect on the date hereof (it being understood that your
continued employment as the CEO of Visterra, Inc. shall not itself be deemed to violate such provisions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions of Appointment</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer of employment is contingent on your continued employment eligibility in accordance with the US immigration and Naturalization
requirements, if appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>At-Will Appointment</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
appointment with the Company will be at-will. This means that you will have the right to terminate your relationship with the
Company at any time for any reason. Similarly, the Company will have the right to terminate its relationship with you at any time
for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
shall be entitled to enter into any indemnification agreement generally offered to the Company&rsquo;s other directors and/or
executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amounts paid to you during or following your relationship with the Company shall be subject to withholding and other employment
taxes imposed by applicable law, and the Company shall withhold from any payments under this offer letter all federal, state and
local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely
responsible for the payment of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter may be executed by .pdf or facsimile signatures in any number of counterparts, each of which shall be deemed an original,
but all such counterparts shall together constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer letter shall be construed and enforced in accordance with, and the laws of the State of New York, without giving effect
to the conflicts of law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notices required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be deemed
to have been given when hand delivered or mailed by registered or certified mail, if to the Company, to its chief legal officer
at the address above, and if to you at the most recent address in the Company&rsquo;s records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
acknowledge your acceptance of this offer by returning a signed copy of this offer letter. If there are any other agreements of
any type that you are aware of that may impact or limit your ability to perform your job at the Company, please let us know as
soon as possible. Please also send to us any employment agreement, confidentiality agreement on non-competition agreement or any
similar agreement that may bear on your ability to assume the position of Executive Chairman of the Company. In accepting this
offer, you represent and warrant to the Company that you are not subject to any legal or contractual restrictions that would in
any way impair your ability to perform your duties and responsibilities to the Company, and that all information you provided
to the Company is accurate and complete in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formalities
aside, we are very excited about having you join our team. Your skills and experiences are a great match with our goals, and I
anticipate you being a critical part of the Company&rsquo;s success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Steven H. Rouhandeh</I></FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 47%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    H. Rouhandeh,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Executive
    Chairman</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Abeona
    Therapeutics Inc.</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED
AND AGREED:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    <U>April 15, 2020</U></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Pereira</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Pereira</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Pereira Offer Letter]</I></FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Abeona Therapeutics Appoints Brian Pereira
and Shawn Tomasello to the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>Company appoints experienced industry leaders
Brian Pereira as Executive Chairman and<BR>
Shawn Tomasello as Independent Board Member</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEW YORK and CLEVELAND, Apr. 21, 2020 &mdash;
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian
Pereira, M.D. and Shawn Tomasello, M.B.A. as Executive Chairman and Independent Board Member, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;On behalf of the Board, I am pleased
to welcome Brian and Shawn, and look forward to collaborating with them as we guide Abeona to success,&rdquo; said Steven H. Rouhandeh,
former Executive Chairman and current Director. &ldquo;Each brings seasoned insights, leadership, and an array of knowledge that
will be extremely valuable as the Company evolves from a clinical to commercial-stage organization.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Pereira, President and CEO of Visterra,
Inc. (ACQ: Otsuka America, Inc.), brings proven leadership to Abeona fostered during a distinguished career in guiding several
biopharma companies to success. Equally, Ms. Tomasello has extensive experience in several leadership roles, most notably as Chief
Commercial Officer (CCO) at cell therapy pioneer Kite Pharmaceuticals (ACQ: Gilead).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;With an impressive clinical pipeline
of gene and cell therapies, a novel capsid platform, and world-class GMP manufacturing operations, Abeona has tremendous potential
to be a leader in the exciting field of genetic medicine that is making treatment for those with rare genetic diseases a reality,&rdquo;
said Dr. Pereira. &ldquo;Fulfilling the promise of Abeona&rsquo;s mission, led by the most advanced gene therapy program in Recessive
Dystrophic Epidermolysis Bullosa, is central to my commitment to the company and its investors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ms. Tomasello said, &ldquo;My past experiences
have several parallels to the opportunity at Abeona, most notably at Kite, which was a true innovator in the fields of autologous
cell therapy, biotech, and medicine as a whole. Moreover, Abeona&rsquo;s fully-integrated business has a range of unique qualities
rarely found in a company of its size, and has it poised to reach its full potential.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Pereira and Ms. Tomasello were nominated
by funds affiliated with Great Point Partners, LLC (GPP) pursuant to the previously disclosed letter agreement entered into as
part of the Company&rsquo;s December 24, 2019 underwritten public offering, which was supported by a considerable investment from
GPP. As contemplated by that agreement, former Executive Chairman Steven H. Rouhandeh has remained as a Director and Richard Van
Duyne and Mark Alvino have resigned from the Board. The Board has formed a search committee to, with the assistance of a leading
executive search firm, identify a new highly qualified independent director to add to the Board, who would also serve as Chair
of the Audit Committee. Dr. Pereira and Ms. Tomasello are each independent of GPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Pereira continued, &ldquo;On behalf of
the Board and all Abeona employees, I am grateful to Steve, Dick, and Mark for their service and dedication to the company. We
wish Dick and Mark well and welcome continued leadership from Steve as a Board Director. I look forward to working with Joao Siffert,
CEO, and his team in making the promise of Abeona a reality.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
Pereira brings over 30 years of expertise to Abeona as a veteran biopharmaceutical leader. His experience in financing and growing
companies is seen at Visterra, where he continues to serve as President and CEO following the Company&rsquo;s 2018 acquisition
by Otsuka America, Inc. Previously, Dr. Pereira served as the President and CEO of AMAG Pharmaceuticals where he built the clinical
development, manufacturing, supply-chain, and commercial infrastructure for Feraheme</FONT><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
underpinned by four financing rounds at increasing valuations. Previously, he held senior roles at Tufts Medical Center including
President and CEO of a Physician Organization. Currently, Dr. Pereira serves as Chairman of the Board of Directors of Africa Healthcare
Network and serves on the Boards of KalVista, Cullinan Pearl and the American India Foundation. He earned a medical degree (M.B.B.S.)
from St. John&rsquo;s Medical College, M.D. (Medicine), D.M. (Nephrology) from the Post Graduate Institute, and M.B.A. from Kellogg
Graduate School of Management at Northwestern University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ms. Tomasello brings over 30 years of experience
in biopharmaceutical industry to Abeona. As CCO, she was a key executive in the $11.9 billion Kite Pharma/Gilead acquisition in
2017. Prior to joining Kite, Ms. Tomasello was the CCO of Commercial and Medical Affairs at Pharmacyclics, surging its market cap
from $8 billion to $19 billion, and culminating in the 2015 acquisition by AbbVie for $21 billion. She brings extensive strategic
experience in building world class organizations encompassing commercial, compliance, regulatory, pricing, and medical affairs
functions. Ms. Tomasello built the foundation for her career with leadership roles at Celgene Corporation, Genentech, Pfizer Laboratories,
Miles Pharmaceuticals and Proctor &amp; Gamble. She currently serves on the Board of Principia BioPharma, Urogen Pharma, Mesoblast
Ltd., Gamida Cell, and Centrexion Therapeutics. Ms. Tomasello earned a B.S. in Marketing from the University of Cincinnati and
M.B.A. from Murray State University, KY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Abeona Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Abeona Therapeutics Inc. is a clinical-stage
biopharmaceutical company developing gene and cell therapies for serious diseases. The Company&rsquo;s clinical programs include
EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101,
novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Company&rsquo;s
portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona
has received numerous regulatory designations from the FDA and EMA for its pipeline candidates, including Regenerative Medicine
Advanced Therapy designation for two candidates (EB-101 and ABO-102). <U>www.abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains certain statements
that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements about the Company&rsquo;s
pipeline of product candidates and clinical trials, including its gene therapy designed to address Recessive Dystrophic Epidermolysis
Bullosa; commercialization prospects; the Company&rsquo;s novel capsid platform; the Company&rsquo;s manufacturing operations;
and the ongoing search for a suitable candidate to join the Company&rsquo;s Board of Directors and Audit Committee. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not
limited to the ongoing effects of the coronavirus (COVID-19) pandemic, continued interest in our rare disease portfolio, our ability
to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory
agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our
products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global
economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in
the Company&rsquo;s Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other periodic reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or
update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information,
future developments or otherwise, except as required by the federal securities laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Scott Santiamo<BR>
Director, Corporate Communications<BR>
Abeona Therapeutics Inc.<BR>
+1 (718) 344-5843<BR>
<U>ssantiamo@abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dan Ferry<BR>
LifeSci Advisors, LLC<BR>
+1 (617) 535-7746<BR>
<U>daniel@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "P < # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#'(AE7#*1@BO+_#GB)_#'BB'5+#S/(CD(:-SS)"3RK8XSC]<5]&_\(!X3_Z
M%C_W[KDOB'\-=,E\,RW>A:=%;7EGF7;"N/-3^)<>O<?3'>M*=6DO=2W,ZE.J
M_>;V/1["]M]2L(+VUD\R"=!)&P[@C->?_'#_ )$>W_Z_H_\ T!ZY_P""WBXH
MS^&;R3@[I;//8]63_P!F'_ JZ#XX'_BA[?\ Z_X__0'K)0Y*J1I*:G2;+?P<
MVGX>V^W&1/+NQZ[J[_%?/7PU^(L'A&VFTW4[>5K*:3SHY8AED; !R#U7@=.F
M.^:]/C^+'@N1<MJYC/\ =:VEX_)2**U*?.VD%&K#D2;.W_&O-_C9&7\"(P&=
MEY&Q]N&']:TV^*_@M%)_MC<<=%MI>?\ QVO+_B/X_7QG+:Z/HL$S6BR!LE/G
MFEZ !1V&?Q)]J*5.?.FT%6I#D:3.X^!V/^$(NL9_X_WSG_<2JWQUC)\-::_.
M%N\?FA_PKL? OAX^%_"=GITF/M.#).1_ST;DC\.!^%5/B3X>E\2>#+FVMHS)
M=PLMQ @_B9<Y'UVEJ%->VYO,;@_8\O6QY'X9^'GBS7/#UKJ.F:Q;P6<V[RXV
MN95*X8J>%7'4&M8?";QUC_D/6W_@9-_\347PY^)5MX5T]M$UJ"X$*2LT<RC)
MBSU5EZXSD_C7HR?%?P4X_P"0S@^]M+_\36U2=52=D8TX4G%7?XGG_P#PJ;QW
M_P!!ZV_\#)O_ (FH+CX->,+O;]IU6PFV_=\RYE;'TRE>C2?%CP7&IVZN9&_N
MK;R<_FH%>9>.?B7>>(]3L[;PU/J-I%%E<P2M&\[L0 -JGG&./J:4)5I/:WR"
M<:*6]_F>R^#M&G\/>$K#2KAHWFMT8.T9)4DL6XR!ZUY=\>5;[;HS\[?+D'XY
M%>L>&K2]L?#6GVVHSR3WJ0+Y\DC[V+]3D]\=/PKB_C-X?N-7\-07]I$TLNGR
M,[HO7RV'S''?!"_AFL:4K5;LVJQO2LCK_!I'_"%:%W_T"#_T!:W.E>'?#KXI
M6&C:-'HNN>:BP,1!<JN\!#SM8=>#G&,\?2N^'Q5\%LN?[;&/>WE_^(I3I34G
MH.G5ARK4[.O&_CTG^C:%)W5YES]0G^%=1<?%WP= A:/4);@C^&.W<'_QX"O(
MO&'B:]^(_BBVMM.M9?)4^59V^!O.?O,WH3@9[ +^-:4*<E/F:M8BO4BX<J=[
MGN'PX5E^'FBA^OD9Y],G%<9\>?\ D"Z3_P!?+_\ H->FZ-8+I6BV.GAMPM8$
MBW?WMJ@9KS/X\_\ (%TC_KY?_P!!J:3O6N555J-CL/AJQ;X>:*6Y/DD?^/&N
MK%<I\-/^2=:+_P!<3_Z&U=8*RG\3-:?P(05\]>,.?CR >1]LM/\ T".OH4=*
M^>?%_P#R7D?]?MG_ .@1UMAOB?H8XGX5ZGT+VS7B_P 4/B%K%EXB;0M$N&MU
MA51,\:@N[L,X![8!'3OFO:<\5\Y?$".\\._%4ZM/;%XC<17<)Z+(%VG&?J,4
ML/&+GJ/$2:AH7K7P)\2]4C$ES?W$&X;A]JOV+?D"2/QJTGPM\?)\RZ]&#Z"]
ME_PKNK7XN^#KB%7EOY;5F'W);=RP_P"^0PJP?BMX) _Y#8_"VE_^(JW4JK[/
MX&:ITOYOQ/-YM&^*'A17U!+RXN;>!2TH%SYJ;>^4)R?J!D57^!ISXWO#_P!0
M^3_T9'7<:[\9/#EO83#3&EO[EE(C7RF1,^K%L''X5Q'P..?'%YGJ=/D_]&1U
M=Y.G)R5B&HJI%1=SZ#HHHKB.\**** "BBB@!O>O,_BS-&?[.AX\T%F/^[BO2
M+FXCMK=YI6"HBEF)]*\!\2ZS)KFLS7C'Y"=L2_W5'2L*\DHV/,S.LHTN3JS"
MDJN_3%3R5-I-F=0UJRLUY\V95Q^-131XE-7:1V?Q$;^R_AMH.E]&E*EA]!NK
MRJ+J*]$^-%XK:_I^GH?DMK?=CZ\#^5>=Q=OK7TF$CRTD>CB_CLNA=AKJ/#'B
M*\\.WOGVQW1MQ)$>C"N8@!) ')K46":';YL4D>[D;U(S73*,9+ED><Y2@^:/
M0]KTSXAZ->HHF=[60]1(./SKK(I4GB26)PZ,,JPZ$5Y#X%\.V6MR3/>2DB''
M[D'!/O\ 2O78(([:!(84"1H-JJ.PKQ<3"G3ERP/?P%:M5AS5+6Z$U%%%<QWA
M1110!Q%U\+?#%_J<FH7=O<37$LIED+SL0S9ST]/:NT"A1M P!V%.HIN3>[)4
M5'9"T444B@HHHH XB/X6^%X=474;>VG@N%F\Y#%,RA&SD8'8>U;OB'PWIWBC
M3TL=4C=X$D$H".5.X CM]36S13<FW>Y"A%*UCDV^'/AB318-)FT[S;:!F:)G
MD;S$+')PXYQ[=*PI_@EX5E?<DNHPC^[',I'_ (\IKTG-&*I5)K9B=*#W1YQ%
M\$_"D?WGU"7_ 'YQ_1170Z)X"\-^'IQ<6&F1BX'W9Y&,C+]-W3\*Z:BAU)O=
M@J<%LA:***@T.8UOP'X:\0SM<7^F1FX;K-&2CGZE?O?CFN>?X)^%'Z/J"?[L
MX_JM>CFBJ52:V9FZ<'NCSJ#X*^$XN7%]-[23X_\ 00*Z/1/!'ASP[.9]-TR.
M*X(QYK$NP^A8G'X5T76@4.I-[L%3@MD+1114FAQVJ_#+PGJ\S32Z4L,SGYGM
MV,>?P''Z5CO\$?"K_=EU%/99E_JM>D45:JS6S,W2@]T>=Q?!;PG&?F6]E_WY
M_P# "NHT/PCH7APEM+TZ*"1@09>6<CTW-DX]JW**4JDWNPC3A'9!6%XD\)Z5
MXKMX(=4CD=(6+H$<KR1CM6[14IM.Z*:35F4=(TJUT32X--LE9;:!=J*S;CC.
M>OXU>HH]J!I!7*WWP_T'4?$?]O7$,QOQ)')O$I W(%"\?\!%=5133:V$XI[A
MBLK7/#VE^(K+[)JMHEQ#N#*&)!4^H8<BM:DI)VU0VD]&>=W/P7\)W#$QB]M_
M:*?_ .*!JN/@=X8[W6IGZS)_\17IM%:>UGW,_8T^QP^E?"KPKI,Z3+9/<S(<
MJ]S(7P?]WA?TJ_X=\ Z%X7U"2^TR&9)Y(C$Q>4L-I(/?W45U%!J7.3W92IP6
MR%HHHJ2PHHHH **2H;AWCMY&C0NZJ2JCN:!-V.&^(.KRRF'0+'+SW!'FA>N.
MR_C3M'^&NGQ6JOJ@:>X(!90V%7VJ_P"&/#LL-U-K6JJ&U"X8L%//E#T^M=;T
M[5A&',^>1PT\/[63JU5OLNR/+?&_@+3['19=2TU&A>#YGCSD,M8/PNTW[;XK
M^TLN8[6,OG_:/ KTOQY<);^"]29B 6CV#ZFLKX7:.;#PV;R5<2W;;^?[HX%:
M<JOH92P\?K,>5>9D>+?A??\ B;Q;+J2W\45K(BK@J2RXKF/&'PQ;PSI U&TN
MWN8T($P9<%1ZU[S574+*'4;">SG4-%,A1@?>NRGBIQ:UT1U5<-":>FK/!OAC
M!!<>,[9)XUD4([*&&1N KW#5=$L-9M#;W=NC+CY6 P5^AKQWP5ILVB?$Y-/F
M!WPM(F?5<<'\J]UK3&3?M%*+Z&."IKV;C)=3R6Y\/ZKX+U-=0LBT]JI^\/[O
MHPKTG1]6M]9L$NK=L@_>7NI]*O.JNC*P!4]016=8:'9:9=S7%HAC,OWD!^7\
MJQJ555C[VZ+I8:5"I^[?NOIV]#5HHHK [0JEJFIVVCZ=-?W9<00@%RB%CUQT
M'UJ[1BD!Q#?%;PL@R\UVHZ9-JX_I5W2O'^A:SJ4.GVDER;B;.P/;LHX!/4CT
M%4/B;_R#-$Q_T&+?_P!FKM\>U:OE44[$J]R"\NXK"QGO)R1%!&TKD#)VJ,GC
M\*CTS4K;6--@U"T8M;SKO1F7!(^E5?$__(J:OC_GRF_] -<)X.O/&\?A'34T
M_2M+ELQ#^Z>6=E=ER>HJ8PYHW&W9G?:SKECH-M#<7[ND<LRP*50M\S9QT^E:
M8KR#QS=>+)M.TY=;T_3K>U_M&$A[:9F;=\V!@]NM>O#I1*'*DP3NSF=9\=Z'
MH.IMI]]-.+E4#E8X&?Y3TZ51_P"%I^&?^>EY_P" C_X5BZC-K4/Q<O6T.UM;
MBX.F('6Y<JH7<.1COG%;7V[XB?\ 0'T3_P "&K1PBDO\R;L[""59X(YDSLD4
M,N1@X-8.O>-M%\.7\=EJ,LRW$D?FJL<+/E<D=OH:Z+ZUYKXFOKVP^+&G36&F
MOJ$_]EL/(64(<;VYR:BG%2=F5)V-8?%'PR6 \Z[ /<VCX_E72Z3K%AK=B+W3
M;E;BW9BNY01AAU!!Y!KFW\5^*%0M_P (-<G'9;U"?Y57^%A$N@7]R3&LMQJ$
MLDL,:L! WR_)R.H]JJ4$HW_6XD]3NZPM<\7:+X=O;6TU.[\J6Y^X I.!G&6Q
MT'O[&M2_OH-,L)[ZZ?9! A=V/8"O)]'U'PWXBCUG5?$FJ6D5SJ@:"*!Y?FMH
M5/RX_P!K(!_#/>IIPOJ]@D['L0((S37<(C.W11DUPOPU\2)J-A-HL]U'<7>F
MMY:RHV1-"#A7'\OR]:[:Z_X\YO\ KFW\J4HN,K,:=U<X\?%3PNPRLUX1ZBU?
M_"K>G?$3PWJ5[%:17<L<TSA(EF@=-S'H,D5R?@?Q+K%AX1L[:U\*7M]"F_;<
M1RJ%?+L>!^./PJYK/_"1^,Y=-LV\,SZ9;V]['<2W,TZDJJYS@?C6SIQ3:_4G
MF9Z77):C\1?#VF:E<Z?<37'VBW;;(([=F /U KK:\JTV;Q'#XZ\6_P!@V=C<
M W$7G?:92NWY3C&/QK*G%2O<;=CHH?B;X<GGCA26\+2,%7-H_4G'I79]JX^T
MN_'C7L"W>E:0EL9%$K1SL65,\D>^*[&E-);#3,RVUJRO-8O=)A=C=V2HTRE2
M  PR,'O6E7$Z#_R5/Q7_ -<;7_T"NVHE&S!.YFZ+K=EK^G+?V#L]NS,F60J<
M@X/!JAKOC+2?#EW';:@]P))$\Q1' SC&2.H^E9'PF_Y$:/\ Z^9O_0J[C%$D
MHR:Z G='$CXK>%]Y437>X=5^ROD?I70:%XAL/$5G)=:>TIB23RV\R,H=V >A
M^HKG="_Y*MXK_P"N-K_Z *[CVIU%%:)"5S,O]<L=-U+3["ZD99[]V2 !"0Q7
M&<GMU%:9KA?&O_([^"O^OJ;_ -!6NZJ91LD^XTSF=9\=:!H5X]G=W;FZ0 O#
M#$SE<],X&*SH_BIX9:0+++=P _QRVS 5#X 53XC\92GESJ;(3WP"V*['4X;:
MXTJ[AO&V6LD#K,V<;4*G)S]*MJ,=&A:O4G@GBN((YX9%DBD4,CH<A@>A!JEK
M&NZ;H-F+K4[I;>)FVKD$ECZ #DU#X8@TRV\.6<.CSF?3T4B&3?NR-QSS]<U@
M>.M,N+[5- NM/N[!-3M)Y)+>VO6P)^%SM]Q@?GU%3&*<K,;>@'XJ^& W^LO#
M'_ST%J^W^5=-I.M:?KUE]LTVX6>'<4)4$%6'4$'D&N8.J_$->OAO3'_W;S&?
MS-2>!KVSN;G6XX]);3=2CNLW\/G&16D;/S ].>>GM5RBK77YW$GJ=K111610
M4444 %%%% !1110!DZ]H5OXAT\6=TSK$)%<[3UP>E:$$$=O D,2A8T 55'85
M+F@4$J*O?J+111048S^'+"3Q)%KNPB\CC,>0>"/>MBDP*7I0Y7)44MA:***"
M@HHHH **** ,/Q)X>7Q%;64+7)@%K>1W60F[=LS\O7CKUK;Z4M)1?H%BIJ=E
M_:.E7=D7,?VF%X=X&=NX$9_6H- TE="T*STQ9C,+:/8'*[=WX5I447Z!8PO$
M_AQ/$UA;6KW+6XANDN-P3=NVYXZ^];HI:2B^E@L<=J_@R]OO$TNN:?K\^G3R
M0+ XC@5\J#GJ3]*9_P (CXF_Z'N]_P# 2/\ QKL\4N*KG8N5$-M')#;112RF
M61$"M(1@N0.3^-9,WAU9O&-OXA-PP>&T-L(-F0<DG=G/O6[14W&)UK$\-^'U
M\/07T*W)G%U>27>2FW;OQ\O7GIUK<HHOT P/%'AT^)K2"REO'@LUF62XC1<F
M=1_#G/ _/M5I?#>A  #1M/P/^G5/\*U:*+NU@.7N/!UH-?T_5]+=--FM<K(L
M$(V3QGJK 8]^?\*Z26/S(G3IN4KFGTM%V]Q6,;PSH8\.:!;Z6)S.(=W[PKMS
MN8MTR?6MBEHH;N[L8E<1<>!M177-2U+3?$UQIYOY%DDCCMU;H,#DGZ_G7<4F
M*:DX["M<XQ/"?B1'5F\<7C $$K]DCY]NM=GVHI:)2<MPM8Y#6?!3WNN2:UI>
MM7>E7TR*DS1*'20+P,J?P_*JS>#/$<Z[+CQS?F(_>$5NL;?]] UV^**:J20<
MJ,O0-#M?#NCPZ99ES#%GYI#EF).236I12U+=W=C,.Q\/K9>*-5UP7)=K](D,
M13 38N.N><UN4@I31>^X&#K'AU-7UO1M1:Y,1TR5Y @3/F;@!C.>.E;M%%#;
M>@'&7_@69M:N-5T77KO2)KIMUPD:!XY&QUVG'/7KGJ:@G\#Z[?0M;W_C6^EM
MI 5DCCMUC+*>HR#7=45?M)6%RHH:1I=OHNDVVFV@(@MT"+NZGU)]R>:S_$GA
M>#Q(EJ[W5Q:7=HYDM[BW;#1L1S_(?E6_2U*;O<+=#AQX-\1A0C>.M0,?M;KN
M_P"^LUL>&O"UKX:AN?)GGN;FZD\RXN;AMSR-VS^9_.M^BG*;:L%D+1114C"B
MBB@ HHI#TXZT %'>LS1;^34-.\RX"+<1R/%*J= RL15#1M=N;_5989DC%M(K
MO:N@.65'*G/Z'\:CG6GF1SK3S.BHK+EU"7^WX=/B";! TTY(.<9VJ!^.?RJ_
M+<0VZ[YI8XQZNP%4G<I-,EHIJ.DBAD8,IZ$'(J%[RVB;$EQ$IW;?F<#GTHN%
MR=AQ0HP*S]8O9;'3_/A"EO-C3YAD89U4_H:NF1!((RZAV&0N>2*+ZV"^MB6D
MJN'E^W,IDB\H1@A!]_=D\GV_^O3GN8(BWF31IM W;F QGIFBX$U%-CD610R,
M&4]"#D4R2YAA=4DFC1F^Z&8 F@9-14:2)(NY65@#C(.>:DI@)1699:U97LDR
M1SH&CE,6&<?,>.1SR.:T))$B4O(ZHH[L<"DFF)-,DHJ**>*==T,B2+ZHP(I)
M9XH%W32I&#T+L!3N.Y,:*B25)"RHZL5QD YQ39;F" J)IHXRW0.X&:5PN345
M&SHL9D+ (!DL3QBJ6G:Q::G$KPRJ"Q8!&8;N"1TS[9HNMA76QHT5EOJ;1ZX]
MI(8TMTM1-N8X(.XKU].*T8Y$E0/&ZNIZ%3D4)I@FF2"@U#+<PV^/.FCCSTWL
M%S3U8,H*D$>HIW'<=2U6-Y;AU0SQ!F)51O&2?2K.: $HJCJ6I0:59FXN,[=R
MJ ",G) XS]:L0W,-P"894DQU*L#BE=7L*ZO8FI:@:ZMXI%CDGC5ST5G )J8<
MTQW"BFLP122< <YK&TC4Y=2O;D^?;"!)'CCB09D.TXW$YZ?AWI-V=B6[.QN4
ME5X6E:></)$R*PV*GWE&T?>]\Y_"E>[MX@2\\2@-M.7 Y]/K0,L4E (89!R#
MW%5Y;N&,LGFQ^<%+!"PS^5%T.Y8HJAI%W)?:1:74NT22Q*[!1QDBK]"=U<2=
MU<,TM0&ZMQ+Y+3Q"0_P%QG\JGZTQW"DI:@-U )?*,\8D_N;QG\J N3T5&\BQ
MH7=PJJ,DL< 4CR*@!=E7<0HR<9/I0!**#43R)& 7=5R<#)QS217$-P"898Y
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MHVWIGWJ:[L+:_15N81($.5/0J?8]14\CM87*[6,J*"&V\8A+:-8UELF:54
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0*20N2>IR>ON35CM6AH?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
